QC
PTCT icon

Quadrature Capital’s PTC Therapeutics PTCT Stock Holding History

Quadrature Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59M Buy
+44,005
New +$3.18M 0.03% 358
2025
Q3 		– Sell
-9,582
Closed -$468K – 1402
2025
Q2 		$468K Sell
9,582
-3,098
-24% -$147K 0.01% 588
2025
Q1 		$646K Buy
+12,680
New +$633K 0.01% 520

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Quadrature Capital's PTCT Position: Q2 2026 in Review

Quadrature Capital opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 44,005 shares worth $3.59M. The stake represents 0.03% of the portfolio and ranks #358 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in PTCT as recently as Q2 2025.

Quadrature Capital first reported a position in PTCT in Q1 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Quadrature Capital held 44,005 shares of PTC Therapeutics worth $3.59M as of Q2 2026.
  • PTC Therapeutics was a new Quadrature Capital position in Q2 2026.
  • PTC Therapeutics made up 0.03% of Quadrature Capital's portfolio in Q2 2026, its #358 holding.
  • Quadrature Capital first reported a position in PTC Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.